10074-G5: A Benchmark Small-Molecule c-Myc/Max Inhibitor for Cancer Research

Executive Summary: 10074-G5 is a potent small-molecule inhibitor that targets the c-Myc/Max dimerization, a critical step in oncogenic transcription factor signaling (APExBIO). It exhibits verified IC₅₀ values of 15.6 ± 1.5 μM in Daudi cells and 13.5 ± 2.1 μM in HL-60 cells under standard in vitro conditions (García-Castillo et al., 2025). The compound induces cell-cycle arrest and apoptosis, with demonstrated in vivo efficacy in Daudi xenograft models at 20 mg/kg intravenous dosing. High c-Myc expression correlates with aggressive cancers, and 10074-G5 enables direct investigation of c-Myc/Max axis disruption (see Mechanistic Insights). The compound features robust solubility in DMSO (≥37.9 mg/mL) and should be stored at −20°C.

Biological Rationale

c-Myc is a basic helix-loop-helix leucine zipper (bHLH-ZIP) transcription factor. It regulates cell cycle progression, cellular growth, metabolism, differentiation, and apoptosis (García-Castillo et al., 2025). Overexpression of c-Myc is observed in diverse cancers, including prostate, pancreatic, lung, breast, colon, B-cell lymphoma, and leukemias. Elevated c-Myc levels are strongly associated with increased tumor aggressiveness and poor prognosis. Mechanistic studies demonstrate that c-Myc acts through dimerization with Max, which is required for transcriptional activation of oncogenic target genes. Recent evidence highlights that microRNA 196a modulates c-Myc accumulation via downregulation of VCP, which subsequently upregulates TERT and reinforces NFκB signaling—a pathway implicated in the aggressiveness of esophageal adenocarcinoma (García-Castillo et al., 2025). Disrupting the c-Myc/Max axis, therefore, offers a strategic intervention point for studying and modulating oncogenic pathways in cancer research. For an extended mechanistic discussion, see this article, which details translational applications and strategic considerations.

Mechanism of Action of 10074-G5

10074-G5 is a small-molecule inhibitor that directly binds to c-Myc, preventing its dimerization with Max. This inhibition blocks the formation of the c-Myc/Max transcriptional complex, thereby suppressing downstream gene expression critical for oncogenesis (APExBIO product page). At 10 μM, 10074-G5 effectively reduces c-Myc/Max dimerization in vitro and decreases total c-Myc protein levels. This leads to cell cycle arrest, apoptosis, tumor vascular degeneration, tumor cell redifferentiation, and regression in multiple cancer models. The molecular structure of 10074-G5 is N-[1,1'-biphenyl]-2-yl-7-nitro-2,1,3-benzoxadiazol-4-amine (C₁₈H₁₂N₄O₃, MW 332.3), and it is a crystalline solid with high purity (≥98%).

Evidence & Benchmarks

• 10074-G5 exhibits an IC₅₀ of 15.6 ± 1.5 μM in Daudi cells (B-cell lymphoma), as measured by cell viability assays under standard conditions (RPMI-1640, 37°C, 5% CO₂) (García-Castillo et al., 2025).
• IC₅₀ in HL-60 (acute promyelocytic leukemia) cells is 13.5 ± 2.1 μM, using the same conditions (García-Castillo et al., 2025).
• At 10 μM, 10074-G5 inhibits c-Myc/Max dimerization and significantly reduces total c-Myc protein levels in vitro (García-Castillo et al., 2025).
• Intravenous administration at 20 mg/kg for 10 consecutive days significantly suppresses tumor growth in Daudi xenograft mouse models, with no significant effect on body weight (García-Castillo et al., 2025).
• 10074-G5 is soluble in DMSO at ≥37.9 mg/mL and in ethanol at ≥3.53 mg/mL (with ultrasonic assistance); it is insoluble in water (APExBIO).

For comprehensive protocol parameters and benchmarking data, see this reference, which integrates robust evidence for 10074-G5 use in apoptosis and cell cycle arrest models. This article extends those findings by directly mapping quantitative results to molecular mechanisms.

Applications, Limits & Misconceptions

10074-G5 is primarily used in cancer research to interrogate the c-Myc/Max signaling axis. Applications include:

• Apoptosis assays in cancer cell lines with known c-Myc overexpression.
• Cell cycle arrest studies and transcriptional profiling of c-Myc-dependent targets.
• Tumor regression studies in xenograft animal models.
• Mechanistic dissection of microRNA-driven oncogenic signaling (e.g., miR-196a/c-Myc/TERT/NFκB axis).

For advanced workflows and troubleshooting strategies, see this article, which complements the present discussion by offering comparative analysis of c-Myc inhibitors.

Common Pitfalls or Misconceptions

• 10074-G5 is not a direct cytotoxic agent; its efficacy relies on the presence of c-Myc/Max-driven transcriptional activity.
• The compound is insoluble in water; improper solvent use can impair experimental reproducibility.
• Activity benchmarks are specific to validated in vitro and in vivo models; results may not extrapolate to all cancer types.
• Long-term storage of 10074-G5 solutions is not recommended due to potential compound degradation.
• 10074-G5 is not intended for clinical or diagnostic use; it is strictly for research applications.

Workflow Integration & Parameters

10074-G5 (SKU: C5722) from APExBIO is supplied as a crystalline solid (≥98% purity). Recommended storage is at −20°C, protected from light. For cell-based assays, dissolve the compound in DMSO (≥37.9 mg/mL) or ethanol (≥3.53 mg/mL with ultrasonic assistance). Typical working concentrations range from 1–20 μM, with 10 μM effective for c-Myc/Max dimerization inhibition. For in vivo studies, intravenous administration at 20 mg/kg daily for 10 days is validated for Daudi xenograft models. Always include solvent controls and verify c-Myc/Max dependency in your chosen model system. For extended workflow integration, see this article, which details strategic deployment of 10074-G5 in the context of the c-Myc/TERT/NFκB axis. This complements the current article by mapping translational endpoints to molecular benchmarks.

Conclusion & Outlook

10074-G5 is a rigorously benchmarked small-molecule inhibitor targeting the c-Myc/Max dimerization interface—a key regulatory axis in oncogenic transcription factor signaling. Its quantitative efficacy in apoptosis, cell cycle arrest, and in vivo tumor regression models underpins its value in advanced cancer research. As microRNA and transcription factor crosstalk (e.g., miR-196a/c-Myc/TERT/NFκB) becomes increasingly relevant for understanding and targeting cancer aggressiveness, 10074-G5 is positioned as an essential tool for dissecting these mechanisms. Researchers are encouraged to leverage validated protocols and integrate 10074-G5 (see product page) into their anticancer drug development workflows. For thought leadership and future directions, the article here offers a strategic update on deployment in translational research, extending the current evidence base.